European CHMP recommends approval of Trixeo Aerosphere (formoterol / glycopyrronium bromide/ budesonide) for maintenance treatment of COPD

It is intended for use as a maintenance treatment in adults with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid and a long‑acting beta2-agonist (LABA) or combination of a LABA and a long-acting muscarinic antagonist.

Source:

European Medicines Agency